Edition:
United States

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

4.48USD
15 Dec 2017
Change (% chg)

$-0.25 (-5.29%)
Prev Close
$4.73
Open
$4.72
Day's High
$4.72
Day's Low
$4.19
Volume
16,038
Avg. Vol
8,835
52-wk High
$8.56
52-wk Low
$3.58

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 07:30am EST 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article

Avenue Therapeutics doses first patient in postoperative pain trial
Wednesday, 27 Sep 2017 08:00am EDT 

Sept 27 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics announces dosing of first patient in pivotal Phase 3 clinical trial of intravenous tramadol for the management of postoperative pain.Avenue Therapeutics Inc says ‍expect to report topline data in Q2 of 2018​.Avenue Therapeutics Inc - about 405 patients will be enrolled to IV tramadol 50 mg, IV tramadol 25 mg or placebo in a 1:1:1 ratio​.  Full Article

Avenue Therapeutics shares open at $7.60 in debut vs. IPO price of $6.00/share
Tuesday, 27 Jun 2017 10:11am EDT 

June 27 (Reuters) - :Avenue Therapeutics Inc shares open at $7.60 in debut on the NASDAQ versus IPO price of $6.00 per share.  Full Article

BRIEF-Avenue Therapeutics prices IPO of $33 mln of common stock (June 26)
Tuesday, 27 Jun 2017 09:49am EDT 

Corrects source to Avenue Therapeutics from Fortress Biotech:Avenue Therapeutics prices initial public offering of $33,000,000 of common stock.Says initial public offering of 5.50 million common shares priced at $6.00per share.  Full Article

Avenue Therapeutics sees IPO priced between $5-$7/shr
Friday, 23 Jun 2017 06:25am EDT 

June 23 (Reuters) - Avenue Therapeutics Inc ::Avenue Therapeutics Inc sees IPO of 5.0 million shares of common stock to be priced between $5 and $7 per share - SEC filing.Avenue Therapeutics Inc says estimate net proceeds from sale of shares of common stock in IPO will be about $30.0 million.Avenue Therapeutics Inc plans to use about $16 million of IPO proceeds to fund continued clinical research, development initiatives in connection with IV Tramadol.Avenue Therapeutics Inc plans to use about $6 million of IPO proceeds to pay off debts to Fortress and NSC.  Full Article

Avenue Therapeutics says effective immediately, Lucy Lu, will serve as co's CEO
Friday, 2 Jun 2017 09:10am EDT 

June 2 (Reuters) - Avenue Therapeutics Inc :Says effective immediately, Lucy Lu, will serve as co's chief executive officer and president.  Full Article

BRIEF-Avenue Therapeutics reports Q3 loss per share $0.30

* Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights

No consensus analysis data available.